Market News (Page 82) - TendieTensor

Market News Page 82 of 161 • 4,020 articles

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

11/08/2025 01:26 PM • Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care due to a voluntary medical device correction for t:slim X2 insulin pumps that caused a significant stock price drop.

BCpA - Reported unit sales up 6%, revenue up 15%, record market share, and positive outlook for 2026
TNDM - Stock dropped 19.9% after announcing a voluntary medical device correction that could potentially interrupt insulin delivery, suggesting significant product and financial risk

#securities claim #medical device #investor losses #class action

As Cash Continues to Pile Up, Should Investors Buy Berkshire Hathaway Stock or Stay Away?

The Motley Fool • Geoffrey Seiler

As Cash Continues to Pile Up, Should Investors Buy Berkshire Hathaway Stock or Stay Away?

11/08/2025 01:23 PM • Berkshire Hathaway continues to be cautious in the stock market, selling more stocks than buying and accumulating a record $381.6 billion in cash. Warren Buffett sees the market as overvalued and is preparing to hand over investing duties to Greg Abel.

BCpC - Reported unit sales up 6%, revenue up 15%, record market share, and positive outlook for 2026
BRK.A - Strong operating results but cautious investment approach, with no stock buybacks and net stock selling

#cash #market valuation #stock selling #Warren Buffett #investment strategy

3 Must-Own Stocks for the Driverless Vehicle Revolution

The Motley Fool • Daniel Miller

3 Must-Own Stocks for the Driverless Vehicle Revolution

11/08/2025 01:14 PM • The driverless vehicle market is projected to reach $13 trillion by 2030, with three key stocks positioned to benefit: Ambarella, Nvidia, and QuantumScape. Each company offers unique technological advantages in autonomous vehicle development, from AI processing to computing platforms and advanced battery technology.

AMBA - Strong edge AI capabilities, expanding serviceable addressable market from $5.5B to $12.9B by 2031, and well-positioned in automotive AI applications

#autonomous vehicles #driverless technology #electric vehicles #AI #battery innovation

557,006 OshKosh (OSK) Shares Worth $63.2 Million Sold by SG Capital

The Motley Fool • Cory Renauer

557,006 OshKosh (OSK) Shares Worth $63.2 Million Sold by SG Capital

11/08/2025 01:08 PM • SG Capital Management LLC completely exited its stake in Oshkosh Corporation, selling all 557,006 shares in the third quarter of 2025. The sale represents a significant portfolio change, with the company previously holding OSK as its second-largest holding.

OSK - Stock has slightly underperformed the market (8.2% gain vs S&P 500's 12.7%), and the company adjusted its earnings outlook, indicating some economic uncertainty

#institutional investor #stock sale #portfolio management #specialty vehicles

Ferrari Stock Looks Expensive -- or Does It?

The Motley Fool • Lawrence Nga

Ferrari Stock Looks Expensive -- or Does It?

11/08/2025 01:05 PM • Ferrari's stock appears expensive at 41 times earnings, but its unique luxury brand model, high profitability, and scarcity-driven business strategy suggest the premium valuation might be justified for long-term investors.

RACE - High margins (38.3% EBITDA), strong brand power, consistent cash flow growth, and ability to maintain pricing power through limited production

#luxury brand #automotive #premium valuation #scarcity #electrification

Prediction: This Supercharged Growth Stock Will Join Nvidia, Apple, Microsoft, and Alphabet in the $3 Trillion Club Before 2028

The Motley Fool • Danny Vena

Prediction: This Supercharged Growth Stock Will Join Nvidia, Apple, Microsoft, and Alphabet in the $3 Trillion Club Before 2028

11/08/2025 01:02 PM • Broadcom is predicted to reach a $3 trillion market cap by 2028 due to its critical role in the AI ecosystem, with strong growth in AI semiconductors and data center solutions driving its potential expansion.

FLEX - Mentioned as a leading market player without specific recent developments
AVGO - Strong AI-related revenue growth, record quarterly earnings, expanding customer base including OpenAI, and projected 60%+ AI segment growth

#AI #semiconductors #market cap #data centers #technology

Why Iren Limited Rallied Again in October

The Motley Fool • Billy Duberstein

Why Iren Limited Rallied Again in October

11/08/2025 12:30 PM • Iren Limited experienced significant stock growth in October, securing AI cloud contracts, raising $1 billion in convertible notes, and announcing a massive $9.7 billion five-year deal with Microsoft that could expand its annual recurring revenue to $2.5 billion.

IREN - Stock rallied 29.4% in October, secured major cloud contracts, raised significant capital, and signed a transformative deal with Microsoft expanding potential revenue

#AI #cloud computing #data centers #GPUs #technology investment

QLD and SPXL Offer Distinct Leverage for Growth Investors

The Motley Fool • Jake Lerch

QLD and SPXL Offer Distinct Leverage for Growth Investors

11/08/2025 12:21 PM • Two leveraged ETFs, QLD and SPXL, provide different approaches to amplifying market returns. QLD offers 2x Nasdaq-100 exposure with a tech focus, while SPXL provides 3x S&P 500 leverage across broader sectors. Both have significantly outperformed the S&P 500 index over five years.

QLD - Delivers strong 5-year returns of 252% with a CAGR of 28.6%, heavily weighted in technology stocks with top holdings in leading tech companies

#leveraged ETFs #market returns #index tracking #investment strategy

FLR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Fluor Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – FLR

GlobeNewswire Inc. • Rosen Law Firm

FLR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Fluor Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – FLR

11/08/2025 12:21 PM • Rosen Law Firm is investigating a potential securities class action against Fluor Corporation for allegedly making false and misleading statements about project costs and financial guidance during February 18-July 31, 2025.

GOOGL - Mentioned as previous employer of new CTO, with no negative implications
FLR - The lawsuit alleges the company made false statements about project costs, financial guidance, and risk mitigation strategies, which potentially misled investors about the company's true financial condition

#securities lawsuit #class action #investor rights #financial disclosure

e.l.f Beauty Shares Plunge. Should Investors Buy the Stock on the Dip or Stay Away?

The Motley Fool • Geoffrey Seiler

e.l.f Beauty Shares Plunge. Should Investors Buy the Stock on the Dip or Stay Away?

11/08/2025 12:20 PM • e.l.f. Beauty reported Q2 fiscal 2026 results with lower-than-expected guidance, experiencing revenue challenges due to tariffs and shipping adjustments. Despite short-term setbacks, the company maintains long-term growth potential, particularly with its Rhode acquisition.

ELF - Stock dropped 40% year-to-date, missed revenue expectations, but has strong long-term growth opportunities and trades at an attractive valuation

#beauty #cosmetics #tariffs #earnings #Rhode #market share

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

GlobeNewswire Inc. • Vor Bio

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

11/08/2025 11:45 AM • Telitacicept demonstrated a 55% reduction in proteinuria and statistically significant improvements in kidney function during a Phase 3 clinical trial for IgA Nephropathy in China, with a favorable safety profile.

SCS - The company is being acquired, with ongoing negotiations and procedural steps being taken to facilitate the merger
VOR - Successfully achieved primary and secondary endpoints in clinical trial, demonstrating potential therapeutic effectiveness of telitacicept

#telitacicept #IgA Nephropathy #clinical trial #proteinuria #kidney function

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

11/08/2025 11:35 AM • Rosen Law Firm filed a class action lawsuit against Avantor, alleging misrepresentation of competitive positioning and business prospects during the period of March 5, 2024 to October 28, 2025.

AVTR - The lawsuit claims the company misrepresented its competitive positioning, experienced negative effects from increased competition, and made materially false statements about its business operations and prospects

#securities lawsuit #class action #investor rights #stock misrepresentation

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

GlobeNewswire Inc. • Monte Rosa Therapeutics

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

11/08/2025 11:30 AM • Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.

TGT - Mentioned as a platform for wishlist donations, with no significant positive or negative context
GLUE - Company presented promising preclinical data demonstrating potential breakthrough in treating inflammatory diseases, with initial Phase 1 study on track and unique approach to targeting cardiovascular inflammation

#molecular glue degrader #NEK7 #NLRP3 inflammasome #cardiovascular disease #cardiometabolic disease

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire Inc. • Tenaya Therapeutics

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

11/08/2025 11:25 AM • Tenaya Therapeutics announced promising interim clinical results for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy, showing improved biomarkers, reduced hypertrophy, and manageable safety profile in early-stage trials.

TNYA - Presented promising early clinical trial results with positive safety and efficacy signals for TN-201 gene therapy, showing improvements in multiple disease parameters and no significant adverse events

#gene therapy #hypertrophic cardiomyopathy #clinical trial #MYBPC3 #cardiovascular research

3 Cryptocurrencies That Could Make Big Moves in 2026

The Motley Fool • Dominic Basulto

3 Cryptocurrencies That Could Make Big Moves in 2026

11/08/2025 11:17 AM • The article explores potential cryptocurrency opportunities in real-world asset tokenization, highlighting Chainlink, Ondo, and World Liberty Financial as key players in this emerging market trend for 2026.

GS - Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement
GLNK - Down 30% in 2025 but considered a top market cap RWA token with strong potential for real-world asset tokenization infrastructure

#cryptocurrency #tokenization #blockchain #real-world assets #digital finance

IGEL läutet neue Ära der EUC-Transformation und vertrauenswürdigen Endpunktsicherheit ein

GlobeNewswire Inc. • Igel

IGEL läutet neue Ära der EUC-Transformation und vertrauenswürdigen Endpunktsicherheit ein

11/08/2025 11:07 AM • IGEL hosted its flagship event in Frankfurt, showcasing new endpoint security solutions focused on Zero Trust architecture, prevention-oriented security, and digital workplace transformation with key technology partners.

GSpA - Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement
MSFT - Mentioned as a key technology partner collaborating on innovative endpoint solutions

#Zero Trust #Endpoint Security #Digital Workplace #Cybersecurity #Adaptive Desktop

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

11/08/2025 10:46 AM • Rosen Law Firm is investigating potential securities claims for agilon health shareholders after the company suspended its 2025 financial guidance, causing a 51.5% stock price drop on August 5, 2025.

GSpD - Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement
AGL - Company suspended full-year financial guidance, acknowledged more severe industry headwinds than previously expected, and experienced a significant 51.5% stock price decline

#securities claims #investor losses #financial guidance #stock price drop

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

GlobeNewswire Inc. • Regeneron Pharmaceuticals, Inc.

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

11/08/2025 10:46 AM • Regeneron announced positive Phase 2 trial results for two novel factor XI antibodies (REGN7508Cat and REGN9933A2) that demonstrate robust anti-clotting effects with minimal bleeding risk in patients undergoing total knee replacement surgery.

GSpC - Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement
REGN - Successfully demonstrated promising Phase 2 trial results for novel antibodies with potential to improve anticoagulation therapy, showing reduced venous thromboembolism rates and minimal bleeding risks

#factor XI #antibodies #anticoagulation #venous thromboembolism #clinical trials

VFC CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Reminds VF Corporation Investors of the November 11th Deadline for Contacting the Firm Regarding Their Rights

GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

VFC CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Reminds VF Corporation Investors of the November 11th Deadline for Contacting the Firm Regarding Their Rights

11/08/2025 10:42 AM • A class action lawsuit has been filed against V.F. Corporation alleging misleading statements about the company's turnaround plans and Vans brand performance during the period of October 27, 2022 to May 20, 2025.

BAC - Serving as joint sponsor and coordinator for the IPO, indicating a standard professional engagement
VFC - The lawsuit alleges the company made false and misleading statements about its turnaround plans, concealed material adverse facts about the Vans brand, and caused investors to purchase securities at artificially inflated prices

#class action #securities #lawsuit #investor rights

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

GlobeNewswire Inc. • Bridgebio Pharma

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

11/08/2025 10:41 AM • BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis significantly reduces all-cause mortality in variant ATTR-CM populations, with a 69% risk reduction in mortality for patients with the V142I genetic variant.

BACpB - Serving as joint sponsor and coordinator for the IPO, indicating a standard professional engagement
BBIO - Demonstrated significant clinical benefits of acoramidis in reducing mortality for a high-risk patient population, presenting promising research results with potential meaningful impact on patient outcomes

#acoramidis #ATTR-CM #mortality #genetic variant #cardiovascular #transthyretin

LANTHEUS CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Stockholders to Contact the Firm Before November 10th Regarding Their Rights

GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

LANTHEUS CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Stockholders to Contact the Firm Before November 10th Regarding Their Rights

11/08/2025 10:37 AM • A class action lawsuit has been filed against Lantheus Holdings for allegedly making false and misleading statements about Pylarify's competitive position and pricing dynamics between November 2024 and August 2025.

BACpE - Serving as joint sponsor and coordinator for the IPO, indicating a standard professional engagement
LNTH - The lawsuit alleges the company concealed material adverse facts about Pylarify's competitive position, misrepresented pricing dynamics, and made misleading statements about business operations and growth potential

#class action #securities #lawsuit #Pylarify #pricing

Better Artificial Intelligence ETF: iShares Semiconductor vs. the Fidelity MSCI Information Technology Index

The Motley Fool • Robert Izquierdo

Better Artificial Intelligence ETF: iShares Semiconductor vs. the Fidelity MSCI Information Technology Index

11/08/2025 09:30 AM • The article compares two ETFs - iShares Semiconductor (SOXX) and Fidelity MSCI Information Technology Index (FTEC) - highlighting their differences in sector focus, cost, and potential AI-related investment opportunities.

BACpK - Serving as joint sponsor and coordinator for the IPO, indicating a standard professional engagement
SOXX - Focused on semiconductor stocks with high potential gains in AI chip market, but with higher volatility

#ETF #AI #semiconductor #technology #investment

Why Everyone Is Talking About Roblox Stock Right Now

The Motley Fool • Lawrence Nga

Why Everyone Is Talking About Roblox Stock Right Now

11/08/2025 09:30 AM • Roblox is experiencing significant growth in 2025, with 48% revenue increase, 70% surge in bookings, and 151.5 million daily active users. The company is exploring new monetization strategies like regional pricing and advertising, while still working towards profitability.

BACpL - Serving as joint sponsor and coordinator for the IPO, indicating a standard professional engagement
RBLX - Strong user growth (70% increase in daily active users), expanding revenue streams, successful regional pricing strategy, and potential for future profitability through advertising and creator monetization

#gaming platform #user growth #monetization #technology stock #digital engagement

2 No-Brainer Dividend Stocks to Buy With $100 in November

The Motley Fool • Prosper Junior Bakiny

2 No-Brainer Dividend Stocks to Buy With $100 in November

11/08/2025 09:15 AM • The article highlights two dividend stocks, Coca-Cola and Pfizer, as attractive investment options for investors with limited capital. Both companies offer unique strengths: Coca-Cola has a 63-year dividend increase streak and strong brand recognition, while Pfizer presents a low valuation and potential for future growth.

BACpM - Serving as joint sponsor and coordinator for the IPO, indicating a standard professional engagement
KO - Consistently increased dividends for 63 years, strong brand recognition, ability to launch new products, and pricing power in the beverage market

#dividend stocks #investment #Coca-Cola #Pfizer #income investing

Is the Schwab U.S. Dividend Equity ETF a Buy Now?

The Motley Fool • Keith Speights

Is the Schwab U.S. Dividend Equity ETF a Buy Now?

11/08/2025 08:31 AM • The Schwab U.S. Dividend Equity ETF is a dividend-focused fund holding 103 U.S. stocks, offering a 4% yield and reasonable valuation. While its 2025 performance has been underwhelming, it provides steady income and diversification for investors seeking dividend stocks.

BACpN - Serving as joint sponsor and coordinator for the IPO, indicating a standard professional engagement
SCHD - Offers attractive dividend yield and reasonable valuation, but has subpar recent performance and high sector concentration

#dividend #ETF #income investing #stock market #portfolio diversification